News ) in a cash transaction valued at about $430 million. The deal will strengthen Merck’s ophthalmology business and position it for future growth with an expanded portfolio.
Merck said it continues to build upon its long-term commitment to improving therapeutic options for the treatment of eye diseases.Durham, North Carolina-based Inspire Pharma is a biopharmaceutical company focused on developing and commercializing prescription pharmaceutical products for ophthalmic diseases.
Merck said it continues to build upon its long-term commitment to improving therapeutic options for the treatment of eye diseases.”We are delighted that Merck recognized the strength of an integrated platform leveraging the growing AZASITE (azithromycin ophthalmic solution) 1% product opportunity and the strong r…